Triomics, a startup specializing in AI-driven solutions for cancer care, has successfully closed a $22 million Series B funding round. The investment was led by Battery Ventures, with continued support from existing investors including Nexus Venture Partners, Lightspeed, and Y Combinator. The fresh capital will be used to further scale the company’s platform, which is designed to alleviate the administrative burden on oncology centers.

As medical advancements continue to extend patient lifespans, the complexity of oncology records has grown significantly. Modern patient charts often span thousands of pages, incorporating everything from physician notes and pathology reports to imaging scans. Triomics addresses this challenge by utilizing large language models trained specifically on oncology data to automate time-consuming tasks, such as clinical trial matching and appointment preparation. By integrating directly into existing clinical workflows, the platform allows doctors to access verifiable patient summaries without the need to toggle between different software applications.

Beyond clinical support, the platform assists healthcare facilities in meeting regulatory requirements by automating the submission of tumor reports to government registries. The technology has already been adopted by prestigious institutions such as Memorial Sloan Kettering and Yale Cancer Center. Despite a competitive landscape featuring established AI medical scribe providers, Triomics has seen significant momentum, reporting a fourfold increase in its enterprise customer base and a tenfold rise in annualized recurring revenue over the past year.